{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:56:32Z","timestamp":1768384592277,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["GNT1200706"],"award-info":[{"award-number":["GNT1200706"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["GNT2017480"],"award-info":[{"award-number":["GNT2017480"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["GNT1189490"],"award-info":[{"award-number":["GNT1189490"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["GNT2036025"],"award-info":[{"award-number":["GNT2036025"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["GNT2024876"],"award-info":[{"award-number":["GNT2024876"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40273-025-01554-4","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:06:59Z","timestamp":1761725219000},"page":"83-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-658X","authenticated-orcid":false,"given":"Adam","family":"Irving","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"11","key":"1554_CR1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"9","key":"1554_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","volume":"17","author":"JJ Shah","year":"2017","unstructured":"Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17(9):575-83.e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1554_CR3","unstructured":"Pharmaceutical Benefits Advisory Committee. Public Summary Document: Daratumumab \u2013 July 2020 PBAC meeting. Canberra (ACT): Australian Government Department of Health and Aged Care; 2020. [cited 2025 Oct 23]. Available from: https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2020-07\/files\/daratumumab-psd-july-2020.pdf."},{"key":"1554_CR4","unstructured":"Pharmaceutical Benefits Advisory Committee. Public Summary Document: Lenalidomide - August 2019 PBAC meeting. Canberra (ACT): Australian Government Department of Health and Aged Care; 2019. [cited 2025 Oct 23]. Available from: https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2019-08\/files\/lenalidomide-with-bort-and-dex-newly-diagnosed-multiple-myeloma-psd-08-2019.docx.pdf."},{"issue":"10068","key":"1554_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"12","key":"1554_CR6","first-page":"1691","volume":"27","author":"N Narsipur","year":"2021","unstructured":"Narsipur N, Bulla S, Yoo C, Do B, Tran K, Gu D, et al. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021;27(12):1691\u2013702.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1554_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12962-024-00525-4","volume":"22","author":"Z Goudarzi","year":"2024","unstructured":"Goudarzi Z, Shahtaheri RS, Najafpour Z, Hamedifar H, Ebrahimi H. Cost-effectiveness and budget impact analysis of daratumumab, lenalidomide and dexamethasone for relapsed-refractory multiple myeloma. Cost Eff Resour Alloc. 2024;22(1):17.","journal-title":"Cost Eff Resour Alloc"},{"issue":"9","key":"1554_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40273-024-01399-3","volume":"42","author":"A Freitag","year":"2024","unstructured":"Freitag A, Sarri G, Ta A, Gurskyte L, Cherepanov D, Hernandez LG. A systematic review of modeling approaches to evaluate treatments for relapsed refractory multiple myeloma: critical review and considerations for future health economic models. Pharmacoeconomics. 2024;42(9):955\u20131002.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1554_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clml.2016.12.002","volume":"17","author":"K Bergin","year":"2017","unstructured":"Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk. 2017;17(3):133-44.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1554_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/hec.4958","volume":"34","author":"P Ghijben","year":"2025","unstructured":"Ghijben P, Petrie D, Zavarsek S, Chen G, Lancsar E. Behavioral responses to healthcare funding decisions and their impact on value for money: evidence from Australia. Health Econ. 2025;34(7):1239\u201354.","journal-title":"Health Econ"},{"key":"1554_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40273-015-0260-4","volume":"33","author":"HM Blommestein","year":"2015","unstructured":"Blommestein HM, Franken MG, Uyl-de Groot CA. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry. Pharmacoeconomics. 2015;33:551\u201360.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1554_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","volume":"13","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, M\u00f6ller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056\u201360.","journal-title":"Value Health"},{"issue":"8","key":"1554_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308812","volume":"19","author":"A Irving","year":"2024","unstructured":"Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, et al. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS ONE. 2024;19(8):e0308812.","journal-title":"PLoS ONE"},{"issue":"1","key":"1554_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health"},{"key":"1554_CR15","unstructured":"Australian Institute of Health and Welfare. National Death Index [data set]. Canberra (ACT): AIHW; 2025. Linked data supplied by the Australian Institute of Health and Welfare."},{"issue":"1","key":"1554_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jval.2021.07.016","volume":"25","author":"K Degeling","year":"2022","unstructured":"Degeling K, IJzerman MJ, Groothuis-Oudshoorn CG, Franken MD, Koopman M, Clements MS, et al. Comparing modeling approaches for discrete event simulations with competing risks based on censored individual patient data: a simulation study and illustration in colorectal cancer. Value Health. 2022;25(1):104\u201315.","journal-title":"Value Health"},{"issue":"9","key":"1554_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel J, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"2","key":"1554_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5694\/mja2.52366","volume":"221","author":"Q Luo","year":"2024","unstructured":"Luo Q, Jenkin D, Weber MF, Steinberg J, White K, Irving A, et al. Multiple myeloma incidence, mortality, and prevalence estimates and projections, Australia, 1982\u20132043: a statistical modelling study. Med J Aust. 2024;221(2):103\u201310.","journal-title":"Med J Aust"},{"issue":"10","key":"1554_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/hec.1199","volume":"16","author":"A O'Hagan","year":"2007","unstructured":"O\u2019Hagan A, Stevenson M, Madan J. Monte carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ. 2007;16(10):1009\u201323.","journal-title":"Health Econ"},{"key":"1554_CR20","unstructured":"Australian Bureau of Statistics. Consumer Price Index. Canberra (ACT): Australian Bureau of Statistics; 2025 [cited 2025 Oct 18]. Available from: https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia."},{"key":"1554_CR21","unstructured":"Australia Government Department of Health and Aged Care. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0). Canberra (ACT): Australian Government Department of Health and Aged Care; 2016 [cited 2025 Oct 23]. Available from: https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf"},{"key":"1554_CR22","unstructured":"Medical Scientific Advisory Group to Myeloma Australia. Clinical practice guideline: multiple myeloma. Melbourne (VIC): Myeloma Australia; 2022 [cited 2025 Oct 23]. Available from: https:\/\/myeloma.org.au\/msag_myeloma-clinical-practice-guideline-2022_final\/."},{"key":"1554_CR23","unstructured":"Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme Schedule, 2024\u201325. Canberra (ACT): Australian Government Department of Health and Aged Care; 2025 [cited 2025 Oct 23]. Available from: https:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"1554_CR24","unstructured":"Independent Health and Aged Care Pricing Authority. National Efficient Price Determination 2024\u201325: Price weights for admitted acute patients. Canberra (ACT): Independent Health and Aged Care Pricing Authority; 2024 [cited 2025 Oct 23]. Available from: https:\/\/www.ihacpa.gov.au."},{"issue":"15","key":"1554_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19159473","volume":"19","author":"KM Merollini","year":"2022","unstructured":"Merollini KM, Gordon LG, Ho YM, Aitken JF, Kimlin MG. Cancer survivors\u2019 long-term health service costs in Queensland, Australia: results of a population-level data linkage study (cos-Q). Int J Environ Res Public Health. 2022;19(15):9473.","journal-title":"Int J Environ Res Public Health"},{"key":"1554_CR26","first-page":"599","volume":"21","author":"S Acaster","year":"2013","unstructured":"Acaster S, Gaugris S, Velikova G, Yong K, Lloyd A. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2013;21:599\u2013607.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1554_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12874-017-0437-y","volume":"17","author":"K Degeling","year":"2017","unstructured":"Degeling K, IJzerman MJ, Koopman M, Koffijberg H. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Med Res Methodol. 2017;17(1):170.","journal-title":"BMC Med Res Methodol"},{"key":"1554_CR28","volume-title":"Stata statistical software: release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021."},{"key":"1554_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fninf.2014.00030","volume":"8","author":"WJ Goscinski","year":"2014","unstructured":"Goscinski WJ, McIntosh P, Felzmann U, Maksimenko A, Hall CJ, Gureyev T, et al. The multi-modal Australian ScienceS imaging and visualization environment (MASSIVE) high performance computing infrastructure: applications in neuroscience and neuroinformatics research. Front Neuroinform. 2014;8:30.","journal-title":"Front Neuroinform"},{"issue":"6","key":"1554_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/ajr.13189","volume":"32","author":"S Ai","year":"2024","unstructured":"Ai S, Thind A, Parmar G. Differences in survival of patients with multiple myeloma in rural versus metropolitan regions: analysis of population data of an Australian local health district. Aust J Rural Health. 2024;32(6):1207\u201315.","journal-title":"Aust J Rural Health"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01554-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:54:02Z","timestamp":1768366442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01554-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Australian and New Zealand Myeloma and Related Diseases Registry has received funding from AbbVie, Amgen, Antengene, BMS, Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Sanofi and Takeda. These funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bradley Augustson has served on advisory committees for Janssen. Gordon Cook has received consultancy fees from Janssen, Pfizer, Takeda and Sanofi, research funding from Janssen, Takeda and BMS and serves on speakers\u2019 bureaus for Janssen, Menarini and Sanofi. Francesca Gay has received honoraria or participates in advisory committees for Janssen, BMS, Amgen, Sanofi, Pfizer, Regeneron, AstraZeneca, Kite, Roche and Menarini. Georgia McCaughan has received honoraria from Pfizer and Janssen and research funding from Antengene. Peter Mollee has received research funding from Pfizer and Janssen and participates in advisory committees for AbbVie, GSK, Janssen and Pfizer. Andrew Spencer has received consultancy fees from Rheumagen, Celltrion, Haemalogix, BMS and Janssen, honoraria from Haemalogix, Sanofi, Antengene, Thermofisher, BMS, Janssen, Roche, AbbVie and Pfizer, research funding from Haemalogix, Antengene, Janssen and AbbVie, serves on speakers\u2019 bureaus for Sanofi, Thermofisher, BMS, Janssen and Pfizer, and on advisory committees for Haemalogix, Sanofi, Antengene, BMS, Janssen, Roche and Pfizer. Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M. Wood, Elizabeth Moore, Cameron Wellard, Neil Waters and Zoe K. McQuilten have no conflicts that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The Australia and New Zealand Myeloma and Related Diseases Registry data are the property of Monash University and not publicly available because of the sensitive patient information. De-identified data are available for research purposes upon successful application to the Myeloma and Related Diseases Registry Steering Committee for researchers and projects that meet the criteria for access to confidential data, more information can be found at\n                      \n                      . The EpiMAP Myeloma model is an open source using the General Public License version 3 (GPLv3). The online repository can be found at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AI, DP, LF and AH designed the study. Formal analysis and investigation were performed by AI. Data collection was performed by EW, EM, CW, NW, AS and ZM. BA, GC, FG, GM and PM provided clinical supervision. The first draft of the manuscript was written by AI and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}